Roche Holding AG
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Roche Holding AG is a Swiss multinational healthcare company that discovers, develops, and markets innovative medicines and diagnostic tests. The company operates through two primary segments: Pharmaceuticals, which focuses on oncology, immunology, infectious diseases, ophthalmology, and neurology; and Diagnostics, which provides clinical chemistry, coagulation, and molecular diagnostics solutions. Its core products and services include pharmaceutical brands such as Tecentriq (atezolizumab) for cancer immunotherapy, Hemlibra (emicizumab) for hemophilia A, Ocrevus (ocrelizumab) for multiple sclerosis, Evrysdi (risdiplam) for spinal muscular atrophy, and Actemra/RoActemra (tocilizumab) for rheumatoid arthritis and cytokine release syndrome; diagnostic offerings encompass the cobas platform for in vitro diagnostics, including cobas pro integrated solutions, Accu-Chek for diabetes management, and Ventana for pathology testing. Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland, with global operations spanning North America, Europe, Asia-Pacific, Latin America, and the Middle East, serving healthcare professionals, patients, and research institutions. In recent developments, the company expanded its diagnostics portfolio through the 2024 launch of the cobas 5800 analyser system for high-volume clinical chemistry testing and strengthened its oncology pipeline via a strategic collaboration with Regeneron Pharmaceuticals announced in late 2024 to co-develop faricimab for additional indications; additionally, Roche completed the acquisition of Poseida Therapeutics in mid-2025 for $1.5 billion to bolster its cell therapy capabilities in hematology and solid tumors.
ASCO 2026: A quiet conference for European pharma, but AstraZeneca and Roche both have work to do
Olema: The Market Overreacted To Roche's SERD Failure
Isomorphic Labs' $2.1 Billion Fundraise Is The Biggest Bet Yet On AI Drug Discovery
Roche CEO Expects Pharma Portfolio to Deliver Sales Growth Through 2030
Roche gets second European approval for Alzheimer's test
Roche to Buy PathAI for Up to $1.05 Billion to Bolster AI Diagnostics Tools
Switzerland's Roche agrees to acquire US-based PathAI
Roche: Policy Overhang Clears, Fundamentals Intact, Upside Remains Limited But Positive
Iran won't give up its “new nuclear weapon” - the Strait of Hormuz: David Roche
Roche CEO laments Swiss franc strength as drugmaker doubles down on U.S. investment
Roche Backs Full-Year View as Quarterly Sales Rise
Roche Q1 sales down on forex effects
Roche submits multiple sclerosis drug fenebrutinib to regulators despite patient deaths
Roche launches new Elevidys study after feedback from European regulator
C4 Therapeutics, Roche expand partnership with new cancer deal worth over $1 billion
HNL Lab Medicine Celebrates Preferred Partnership With Roche Diagnostics
Eli Lilly Pays $350 Million Upfront in China Biotech Collaboration Deal